Physician profile
Jessica Bustos
NPI 1619175791
$7,289.53
in general payments reported to CMS, 2019-2025
18 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,071 · 2022: $1,148 · 2023: $1,583 · 2024: $1,964 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,071.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $2,525.01 | 2021-2025 | Ztlido |
| Orexo US, INC. | $1,121.99 | 2021-2025 | Zubsolv |
| Collegium Pharmaceutical, INC. | $891.47 | 2021-2025 | Xtampza, Belbuca |
| Indivior INC. | $541.65 | 2021-2025 | Sublocade |
| Ibsa Pharma INC. | $529.16 | 2023-2025 | Tirosint, Licart, Flector |
| Braeburn INC. | $465.39 | 2023-2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $431.48 | 2021-2025 | Relistor |
| Galderma Laboratories, L.P. | $123.53 | 2021 | |
| Boston Scientific Corporation | $123.28 | 2022-2023 | |
| Valinor Pharma, LLC | $119.08 | 2024-2025 | Movantik |
| Medtronic, INC. | $117.77 | 2021-2022 | |
| Redhill Biopharma INC. | $71.45 | 2021-2022 | |
| Nevro Corp. | $57.95 | 2021-2023 | Senza |
| Arbor Pharmaceuticals, INC. | $50.99 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $45.47 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $35.08 | 2025 | |
| Averitas Pharma INC. | $21.66 | 2023 | Qutenza |
| Forte Bio-Pharma LLC | $17.12 | 2023 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Bustos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.